ATE489380T1 - Hydratformen von amg706 - Google Patents

Hydratformen von amg706

Info

Publication number
ATE489380T1
ATE489380T1 AT07717053T AT07717053T ATE489380T1 AT E489380 T1 ATE489380 T1 AT E489380T1 AT 07717053 T AT07717053 T AT 07717053T AT 07717053 T AT07717053 T AT 07717053T AT E489380 T1 ATE489380 T1 AT E489380T1
Authority
AT
Austria
Prior art keywords
amg
amg706
angiogenic
hydrate forms
drug substance
Prior art date
Application number
AT07717053T
Other languages
English (en)
Inventor
Gonzalo Alva
Seshadri Neervannan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE489380T1 publication Critical patent/ATE489380T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Lubricants (AREA)
AT07717053T 2006-02-10 2007-01-26 Hydratformen von amg706 ATE489380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77239706P 2006-02-10 2006-02-10
PCT/US2007/002182 WO2007092178A1 (en) 2006-02-10 2007-01-26 Hydrate forms of amg706

Publications (1)

Publication Number Publication Date
ATE489380T1 true ATE489380T1 (de) 2010-12-15

Family

ID=38003498

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07717053T ATE489380T1 (de) 2006-02-10 2007-01-26 Hydratformen von amg706

Country Status (9)

Country Link
US (1) US7989631B2 (de)
EP (1) EP1987023B1 (de)
JP (2) JP2009526050A (de)
AT (1) ATE489380T1 (de)
AU (1) AU2007212696B2 (de)
CA (1) CA2641713C (de)
DE (1) DE602007010734D1 (de)
ES (1) ES2353482T3 (de)
WO (1) WO2007092178A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE489380T1 (de) * 2006-02-10 2010-12-15 Amgen Inc Hydratformen von amg706
WO2009140549A1 (en) * 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2968113B8 (de) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systeme zur verzögerten intraokularen abgabe schwerlöslicher verbindungen aus einem implantat mit einem portabgabesystem
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
BR112023023128A2 (pt) * 2021-05-06 2024-01-30 Amgen Inc Formulação de sotorasib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797388A (en) * 1984-05-21 1989-01-10 Cetus Corporation Pharmaceutical compositions with galactitol as carrier
JP2762522B2 (ja) 1989-03-06 1998-06-04 藤沢薬品工業株式会社 血管新生阻害剤
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
CA2101571A1 (en) * 1992-09-08 1994-03-09 Elizabeth A. Garofalo Crystalline dihydrate of a cephalosporin dihydrate salt and injectable compositions thereof
USRE39706E1 (en) * 1993-01-15 2007-06-26 Leo Pharma A/S Crystalline form of a vitamin D analogue
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
DE69940808D1 (de) 1998-03-04 2009-06-10 Bristol Myers Squibb Co Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
AU747427B2 (en) 1998-07-10 2002-05-16 Merck & Co., Inc. Novel angiogenesis inhibitors
CA2341409A1 (en) 1998-08-31 2000-03-09 Merck And Co., Inc. Novel angiogenesis inhibitors
ATE329596T1 (de) 1999-03-30 2006-07-15 Novartis Pharma Gmbh Phthalazinderivate zur behandlung von entzündlicher erkrankungen
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
JP5336686B2 (ja) 1999-11-24 2013-11-06 スージェン， インク． 遊離酸または遊離塩基としてイオン化可能な医薬品のための処方
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
ATE489380T1 (de) * 2006-02-10 2010-12-15 Amgen Inc Hydratformen von amg706

Also Published As

Publication number Publication date
EP1987023A1 (de) 2008-11-05
ES2353482T3 (es) 2011-03-02
JP2014055143A (ja) 2014-03-27
CA2641713C (en) 2011-11-22
US7989631B2 (en) 2011-08-02
CA2641713A1 (en) 2007-08-16
JP2009526050A (ja) 2009-07-16
AU2007212696B2 (en) 2011-05-19
US20080039501A1 (en) 2008-02-14
EP1987023B1 (de) 2010-11-24
WO2007092178A1 (en) 2007-08-16
DE602007010734D1 (de) 2011-01-05
AU2007212696A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
DE602007010734D1 (de) Hydratformen von amg706
BR0008058A (pt) Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
ATE322265T1 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
EA201000897A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
MX2008012479A (es) Tratamiento de enfermedades neurodegenerativas.
IL192181A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
ATE462438T1 (de) Verwendung von carrageenan zur behandlung von rhinovirus-infektionen
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2010001116A (es) Derivados novedosos de benzamidina, proceso para la preparacion de estos y composicion farmaceutica para la prevencion o el tratamiento de osteoporosis que comprende a los mismos.
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
DE602006021348D1 (de) Feste form von amg 706 und pharmazeutische zusammensetzungen davon
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
BR112012024522A2 (pt) combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio
ATE545424T1 (de) Zusammensetzungen mit lipoteichonsäure zur verwendung bei der behandlung von pleuraerguss oder pneumothorax
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties